For immunochemical detection of CD25
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CD25/Interleukin-2Rα Chimeric Monoclonal Antibody (Clone Daclizumab)

Item No. 37169

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Cluster of Differentiation 25
  • IL-2Rα
  • Interleukin-2 Receptor Subunit α
  • TAC Antigen
Immunogen
Recombinant human CD25/IL2Rα
Clone Designation
Daclizumab
Formulation (Request formulation change)
200 µg of protein A-affinity purified monoclonal antibody
Storage Buffer
PBS with 0.02% ProClin™ 300
Host
Chimeric Monoclonal Antibody
Isotype
IgG1κ
Applications
FC block
Cross Reactivity
(+) CD25
Species Reactivity
(+) Human(+) Rhesus monkey(+) Cynomolgus monkey
UniProt Accession №
P01589
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    200 µg

    $473

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    CD25, also known as interleukin-2 receptor α (IL-2Rα), is a transmembrane glycoprotein.1 It is composed of two domains, D1 and D2, and associates with the CD122/IL-2β and CD132/IL-2γc subunits to form the heterotrimeric IL-2 receptor. CD25 is expressed in activated T and B cells, regulatory T cells, and lymphokine-activated killer (LAK) cells.2,3,4 Activation of IL-2R on T cells increases the expression of CD25 and leads to T cell proliferation and differentiation, as well as activation-induced T cell death.3,4 ILR2A expression and CD25 protein levels in bone marrow are increased in patients with acute myeloid leukemia (AML) and associated with poor prognosis.3 SNPs in ILR2A and elevated serum levels of a soluble form of CD25 are associated with an increased risk of Graves' disease.5 Cayman's CD25/Interleukin-2Rα Chimeric Monoclonal Antibody (Clone Daclizumab) was produced recombinantly from the original humanized antibody and can be used for flow cytometry (FC). The original antibody was generated by fusing human framework and constant domains to the antigen-binding domain of a mouse anti-CD25/IL2Rα monoclonal antibody, which targets the ERIYHV peptide corresponding to amino acids 116 to 122 of human CD25.6,7

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Stauber, D.J., Debler, E.W., Horton, P.A., et al. Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. USA 103(8), 2788-2793 (2006).

    2. Volkó, J., Kenesei, Á., Zhang, M., et al. IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2Rα therapies. Proc. Natl. Acad. Sci. USA 116(42), 21120-21130 (2019).

    3. Li, J., Ran, Q., Xu, B., et al. Role of CD25 expression on prognosis of acute myeloid leukemia: A literature review and meta-analysis. PLoS One 15(7), e0236124 (2020).

    4. Waldmann, T.A. The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol. Today 14(6), 264-270 (1993).

    5. Lee, H.J., Li, C.W., Hammerstad, S.S., et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J. Autoimmun. 64, 82-90 (2015).

    6. Queen, C., Schneider, W.P., Selick, H.E., et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA. 86(24), 10029-10033 (1989).

    7. Binder, M., Vögtle, F.-N., Michelfelder, S., et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 67(8), 3518-3523 (2007).